|

TRX-221 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Therapex Co., Ltd1

Indications

  • EGFR Mutant Advanced Non-Small Cell Lung Cancer1
  • Carcinoma, Non-Small-Cell Lung1
  • Lung Cancer1
  • Cancer1

Other1 trial

A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.